ATOS

ATOSSA THERAPEUTICS, INC. - 10-Q Summary (Q3 2024)

Business Context and Reporting Period

This report covers the quarterly period ended September 30, 2024. Atossa Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing proprietary medicines for breast cancer and other breast conditions. The company's lead drug candidate is oral (Z)-endoxifen. The company has no current revenue sources and relies on cash reserves and potential future financing to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses decreased by $1.1 million (15%) for the quarter and $1.9 million (8%) for the nine months ended September 30, 2024, compared to the prior year periods.
  • R&D Expenses: Decreased primarily due to lower spending on clinical trials and reduced stock-based compensation.
  • G&A Expenses: Decreased due to lower compensation costs (including severance in the prior year) and insurance premiums, partially offset by higher legal and investor relations fees.
• Impairment Charge: The company recorded a $1.7 million impairment charge on its investment in Dynamic Cell Therapies, Inc. (DCT) for the quarter and nine months ended September 30, 2024. This followed DCT's decision to lay off all employees and wind down operations. The investment balance is now $0.
• Cash Flow: Net cash used in operating activities was $14.0 million for the nine months ended September 30, 2024, a decrease of $1.4 million compared to the prior year period.

Guidance, Outlook, and Risks

• Liquidity: Management believes current cash and cash equivalents ($74.8 million) are sufficient to fund operations for at least the next 12 months. The company expects to incur ongoing losses and will need to raise substantial additional capital in the future.
• Clinical Progress:
  • Karisma-(Z)-endoxifen Study: Preliminary data announced in November 2024 showed significant reduction in mammographic breast density (19.3% and 26.5% for 1mg and 2mg doses, respectively) in premenopausal women.
  • EVANGELINE Study: The PK Run-in Cohort was fully enrolled in July 2024; the Treatment Cohort is expected to initiate in Q4 2024.
  • I-SPY 2 EOP: Enrollment completed for the Phase 2 trial; preliminary data showed (Z)-endoxifen met primary endpoints with significant reduction in Ki-67 biomarkers.
• Risks and Contingencies:
  • Patent Litigation: Intas Pharmaceuticals filed a Post Grant Review (PGR) petition to invalidate a key patent (U.S. Patent No. 11,572,334). The company is actively contesting this.
  • Australian Tax Rebates: The company recorded a liability of $1.5 million regarding the Australian R&D tax incentive program, as it is no longer reasonably assured the full tax position would be sustained under audit.
  • Capital Markets: The company faces risks related to raising capital in a volatile market environment with high interest rates.